Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
Emergency Medicine Unit, Regional Referral Headache Center, Sant'Andrea University Hospital, Rome, Italy.
BioDrugs. 2022 May;36(3):337-339. doi: 10.1007/s40259-022-00532-y. Epub 2022 May 16.
The introduction of new drug classes for migraine, such as monoclonal antibodies that target the calcitonin gene-related peptide (CGRP) or its receptor and small-molecule antagonists of CGRP, have opened a new scenario in a large population of individuals suffering from migraines. The provision of an effective and safe therapy can help overcome the high social and personal costs together with the burden of this disease by offering social, work and economic recovery to the people affected by migraine. Whether the satisfaction of personal and collective unmet needs will be achieved in the vast majority of migraine sufferers now depends only on the efficiency of the organizational care structures dedicated to this socially impactful disease. This path will offer personal benefits and significant psychosocial relief that will help to reduce the enormous current healthcare expenditure necessary for the management of the huge number of individuals suffering from migraines. The new pharmacological classes for prevention must be applied as an interdiction to the chronic phase to express their full rehabilitation potential.
新型偏头痛药物类别的引入，如针对降钙素基因相关肽（CGRP）或其受体的单克隆抗体和 CGRP 的小分子拮抗剂，为大量偏头痛患者开辟了新的治疗前景。提供有效且安全的治疗方法可以帮助克服这种疾病的高社会和个人成本以及负担，为受偏头痛影响的人们提供社会、工作和经济上的恢复。现在，大多数偏头痛患者是否能够满足个人和集体的未满足需求，仅取决于专门针对这种具有社会影响力的疾病的组织护理结构的效率。这条道路将带来个人受益和显著的心理社会缓解，有助于减少管理大量偏头痛患者所需的巨大当前医疗保健支出。新型预防类药物必须作为一种干预措施应用于慢性期，以发挥其全面康复的潜力。
